The Tema Space Innovators ETF (NASA) is preferred over the Procure Space ETF (UFO) due to NASA's larger allocation to SpaceX, including private pre-IPO shares, making up nearly a quarter of the fund. NASA holds SpaceX and its rivals in equal measure, while UFO has twice the exposure to rivals compared to SpaceX. Both ETFs contain many unprofitable companies, which are more vulnerable in market downturns, but NASA's heavier SpaceX focus is seen as a potential advantage for investors bullish on space ventures. The analyst prefers exposure through defense ETFs rather than adding SpaceX's unique risks directly to his portfolio.
The NASA vs. UFO ETF comparison is the subject here, with Pluang market data providing context. For readers following US stocks, 98 of 150 priced shares rose while 52 fell. Notable movers include BABA at USD 111.12 (+4.98%), OPEN at USD 2.33 (-4.51%), and GAP at USD 23.49 (+4.35%) as of Oct 06, 2026 02:21 WIB.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
